Since the dose and schedule of the VEGF-targeted agents are generally kept constant irrespective of cancer types, it is possible that the documented responses to VEGF/VEGFR inhibitors of ccRCC patients are due, in part, to the lower levels of VEGF-A target agents. Here, KDR is linked to nonpapillary renal cell carcinoma.